Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
Status:
Completed
Trial end date:
2020-11-12
Target enrollment:
Participant gender:
Summary
This single-center, open-label, randomized, single and multiple-dose, 3-way sequential study
at 3 dose levels will be performed in healthy subjects. Subjects will be randomized to 1 of
the 3 dose levels. In each dose level, subjects will be administered a single dose in the
fasted state and then a single dose in the fed state, followed by 14 days of dosing to assess
Pharmacokinetics (PK) following multiple dosing.